10 Stocks Leaving Wall Street in the Dust; 4 Hit Fresh Records

3. Moderna Inc. (NASDAQ:MRNA)

Moderna rebounded by 17.02 percent on Tuesday to finish at $39.60 apiece as investors took heart from the preliminary results of its earnings performance in full-year 2025.

At the 44^th Annual JP Morgan Healthcare Conference on Monday, Moderna Inc. (NASDAQ:MRNA) said that it expects to report revenues of $1.9 billion for full-year 2025, or $100 million over the midpoint of its $1.6 billion to $2 billion guidance range communicated during its third quarter earnings call.

For 2026, Moderna Inc. (NASDAQ:MRNA) reaffirmed plans to deliver up to 10 percent growth and further lower its operating expenses to $4.2 billion to $4.6 billion in a bid to break even in 2028.

“In 2025, we strengthened our commercial execution, successfully launched our third product, and continued to advance our mRNA pipeline. At the same time, we reduced our annual operating expenses by approximately $2 billion, significantly exceeding the financial cost reduction commitments we set at the start of the year,” said Moderna Inc. (NASDAQ:MRNA) CEO Stephane Bancel.

“We remain focused on our strategy to build a large seasonal vaccine franchise for at-risk populations, creating a strong cash engine to fund our next phase of innovation in oncology and rare disease. We expect this approach to support up to 10 percent revenue growth in 2026, as we further reduce costs, expand our commercial portfolio with approvals of additional seasonal vaccines, and anticipate multiple clinical data catalysts driven by our late-stage oncology pipeline.”

Official results are set to be released in the second week of next month.